Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
|Videos|March 15, 2021
Dr. Tward discusses his experience with the Prolaris test for prostate cancer
Author(s)Urology Times staff
“It’s an extremely useful tool,” says Jonathan D. Tward, MD, PhD, of the Prolaris test.
Advertisement
“I think that getting a really personalized risk estimator can give you a better handle on how much you need to do to achieve the best outcome,” says Jonathan D. Tward, MD, PhD, in discussing the Prolaris test and how his use of the test has evolved over time. Tward is a professor of radiation oncology at the University of Utah, Salt Lake City.
Advertisement
Related to this article
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.
Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Advertisement
Advertisement